On Wednesday, August 05, Collegium Pharmaceutical COLL will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.
Earnings and Revenue
Sell-side analysts expect Collegium Pharmaceutical's EPS to be near $0.2 on sales of $74.40 million. In the same quarter last year, Collegium Pharmaceutical posted EPS of $-0.140 on sales of $75.04 million. The Wall Street estimate would represent a 242.86% increase in the company's earnings. Here's how the Collegium Pharmaceutical's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q1 2020 | Q4 2020 | Q3 2019 | Q2 2019 |
|---|---|---|---|---|
| EPS Estimate | 0.37 | -0.10 | -0.15 | -0.19 |
| EPS Actual | 0.01 | -0.07 | -0.18 | -0.14 |
| Revenue Estimate | 77.08 M | 73.33 M | 74.46 M | 75.82 M |
| Revenue Actual | 76.51 M | 74.20 M | 72.94 M | 75.04 M |
Stock Performance
Over the last 52-week period, shares are up 54.34%. Given that these returns are generally positive, long-term shareholders can be satisfied going into this earnings release.
Don't be surprised to see the stock move on comments made during its conference call. Collegium Pharmaceutical is scheduled to hold the call at 16:30:00 ET and can be accessed here: https://78449.themediaframe.com/dataconf/productusers/colg/mediaframe/39853/indexl.html
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
